×
Phio Pharmaceuticals EBITDA 2012-2024 | PHIO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Phio Pharmaceuticals ebitda from 2012 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Phio Pharmaceuticals EBITDA 2012-2024 | PHIO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Phio Pharmaceuticals ebitda from 2012 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$88.3B
Takeda Pharmaceutical (TAK)
$46.6B
Merck (MKGAF)
$23B
Astellas Pharma (ALPMY)
$21.6B
Sandoz Group AG (SDZNY)
$18.1B
Summit Therapeutics (SMMT)
$16.5B
United Therapeutics (UTHR)
$15.9B
Shionogi (SGIOY)
$13.3B
Neurocrine Biosciences (NBIX)
$11.7B
Catalent (CTLT)
$10.9B
Orion OYJ (ORINY)
$7.7B
Revolution Medicines (RVMD)
$7.3B
Jazz Pharmaceuticals (JAZZ)
$6.8B
Ionis Pharmaceuticals (IONS)
$6B
Hikma Pharmaceuticals Plc (HKMPF)
$5.7B
Madrigal Pharmaceuticals (MDGL)
$4.6B
Corcept Therapeutics (CORT)
$4.5B
Crinetics Pharmaceuticals (CRNX)
$4B
Dyne Therapeutics (DYN)
$3.5B
PTC Therapeutics (PTCT)
$2.9B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
Arrowhead Pharmaceuticals (ARWR)
$2.4B
Catalyst Pharmaceuticals (CPRX)
$2.4B
Recursion Pharmaceuticals (RXRX)
$2B
Soleno Therapeutics (SLNO)
$1.9B
Centessa Pharmaceuticals (CNTA)
$1.8B
Xencor (XNCR)
$1.6B
Harrow (HROW)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.6B
Cassava Sciences (SAVA)
$1.5B